StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
AMN$29.34+1.28%
Fair $29.34+0.0%

AMN

AMN Healthcare Services, Inc.

Healthcare / Medical Care FacilitiesNYSE

$29.34

+0.37 (+1.28%)

Fairly Valued+0.0%Fair Value $29.34Fund rank 30/100 · Data gapFallback financials|
SA 33/D
F-Score: 6/9
Declining RevenueMargin CompressionLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $239.5M · quality 61.3/100

Data gap 30/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 67/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

33/100

D

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 17Warnings: 3unknown: 17
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Revenue has declined for 3 consecutive years Operating margin has declined for 3 consecutive years ROE is -14.9%, below the 5% threshold
Thesis & Journal · AMNLocal privado en este navegador · AMN Healthcare Services, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.1B

P/E

N/A

•

EV/EBITDA

18.8x

↑

ROE

-14.9%

↓

Gross Margin

28.3%

↓

Debt/Equity

1.25

↑
52-Week Range$29
$15$32

TradingView lightweight chart

AMN price, volumen y niveles de valoración

Último $29.34Periodo +35.6%
Fair value: $29.34

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2009–2025 · 16 años de histórico normalizado

Revenue CAGR

+8.3%

FCF CAGR

+5.8%

FCF margin

8.6%

FCF / Net income

-2.44x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $2.73B · net income $-95.7M · FCF $233.8M

2009-FY → 2025-FY

Gross margin

28.3%+1.4% pts

Operating margin

1.2%+21.4% pts

Net margin

-3.5%+12.6% pts

FCF margin

8.6%-3.9% pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Income Statement
Revenue$2.73B$2.73B$2.98B$3.79B$5.24B$3.98B$2.39B$2.22B$2.14B$1.99B$1.90B$1.46B$1.04B$1.01B$954.0M$887.5M$669.9M$759.8M
Net Income$-95.7M$-95.7M$-147.0M$210.7M$444.1M$327.4M$70.7M$114.0M$141.7M$132.6M$105.8M$81.9M$33.2M$32.9M$17.1M$-26.3M$-52.0M$-122.2M
EBITDA$101.1M$101.1M$71.1M$499.4M$784.2M$581.7M$243.5M$235.4M$244.1M$244.7M$221.3M$149.8M$83.9M$79.0M$67.5M$54.0M$-29.0M$-139.8M
EPS-2.48-2.48-3.855.369.906.811.482.402.912.682.151.680.690.690.37-0.57-1.49-3.75
Gross Margin28.3%28.3%30.8%33.0%32.7%32.9%33.1%33.5%32.6%32.4%32.6%32.1%30.5%29.4%28.3%28.1%27.5%26.9%
Operating Margin1.2%1.2%4.0%9.1%12.3%12.0%6.2%8.0%9.5%10.7%10.1%8.8%6.6%6.5%5.6%4.2%-6.5%-20.2%
Net Margin-3.5%-3.5%-4.9%5.6%8.5%8.2%3.0%5.1%6.6%6.7%5.6%5.6%3.2%3.3%1.8%-3.0%-7.8%-16.1%
Balance Sheet
Debt/Equity1.251.251.551.620.820.721.050.840.690.570.800.520.560.680.871.28——
Current Ratio1.091.09————————————————
Cash Flow
Free Cash Flow$233.8M$233.8M$239.5M$266.8M$572.8M$251.8M$219.1M$189.6M$191.8M$134.0M$112.0M$29.3M$8.5M$51.1M$52.9M$14.7M$3.9M$94.9M
Returns
ROE-14.9%-14.9%-20.8%25.3%42.5%28.2%8.6%15.5%22.2%23.6%23.6%23.5%12.9%15.1%9.4%-19.4%-33.9%-71.5%
Valuation
P/E———13.8311.09—————————————
EV/EBITDA18.7818.7828.968.487.30—————————————
P/B1.761.761.383.514.72—————————————
Growth & Yield
Revenue Growth-8.5%-8.5%-21.3%-27.7%—66.4%7.7%4.0%7.4%4.5%30.0%41.2%2.4%6.1%7.5%32.5%-11.8%—
EPS Growth35.6%35.6%-171.8%-45.9%—360.1%-38.3%-17.5%8.6%24.7%28.0%143.5%0.0%86.5%164.9%61.7%60.3%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +39.0%

Total return

+39.0%

Start / end P/E

n/dx → n/dx

EPS bridge

-3.85 → -2.48

Residual

+39.0%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+39.0%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.